PubMed RSS Feed - -Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case-series

[rss]

Dermatol Ther. 2022 Sep 29:e15848. doi: 10.1111/dth.15848. Online ahead of print.

ABSTRACT

Rosacea is a chronic inflammatory skin disease characterized by facial erythema, papules, pustules, telangiectasia and flushing. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway appears to play a role in the pathogenesis of rosacea. Our study preliminarily explored the efficacy of JAK inhibitor tofacitinib in the treatment of rosacea. We retrospectively reviewed the cases of 21 patients with rosacea who were treated with oral tofacitinib. Patients received oral tofacitinib 5 mg as either monotherapy or adjunctive therapy. We have observed that 15 out of 21 patients (71.4%) patients experienced significant regression of erythema on the face (IGA≤1), and a mean change of -2.24 in the Investigator's Global Assessment (IGA) score was significant improvement from baseline. Treatment with oral tofacitinib might be a potentially effective treatment to ameliorate the symptoms of rosacea.

PMID:36175135 | DOI:10.1111/dth.15848

{url} = URL to article